Rigel Pharmaceuticals is a biotechnology company dedicated to improving the lives of patients through the development and commercialization of novel small molecule drugs. Rigel is focused on immune and hematologic disorders, cancer, and rare diseases and see great opportunity to help patients who have diseases where few to no approved treatment options exist. Rigel's first FDA approved product TAVALISSE® (fostamatinib disodium hexahydrate) tablets was approved in 2018. Please visit www.TAVALISSEhcp.com to see the full Prescribing Information and learn more.
TAVALISSE is a spleen tyrosine kinase (SYK) inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Contact this Exhibitor